Ab­b­Vie bails on So­sei Hep­tares pact for nov­el neu­rol­o­gy can­di­dates in blow to dis­cov­ery out­fit's A-list Rolodex

Japan’s So­sei Hep­tares has built a who’s who list of big-name part­ners look­ing to li­cense the com­pa­nies’ dis­cov­ery-stage G pro­tein-cou­pled re­cep­tors for nov­el neu­rol­o­gy path­ways and be­yond. But with So­sei’s goal of sign­ing two to three deals per year, there are bound to be set­backs — the most re­cent cour­tesy of phar­ma gi­ant Ab­b­Vie.

Ab­b­Vie will walk away from a lega­cy Al­ler­gan li­cens­ing pact with So­sei due to “pipeline de­ci­sions” that will leave So­sei’s mus­carinic ag­o­nist can­di­dates for schiz­o­phre­nia, Alzheimer’s and oth­er neu­ro­log­i­cal con­di­tions seek­ing a new home, the com­pa­nies said Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER